Guideline Summary for Prescribing Insulin Lispro in Continuous Subcutaneous Insulin Infusion (CSII)
Insulin Lispro Specification and Administration Route
- The American Diabetes Association (ADA) recommends prescribing insulin lispro (Humalog) at a concentration of 100 units/mL for use in insulin pumps. 1
- The ADA specifies that insulin lispro should be administered via continuous subcutaneous insulin infusion (CSII) using an insulin pump. 2
Dosage Calculation and Supply Duration
- The ADA advises calculating the prescribed quantity of insulin lispro based on the patient’s total daily insulin dose (TDD), which typically ranges from 0.4 – 1.0 units/kg/day; a starting dose of 0.5 units/kg/day is suggested for metabolically stable individuals. 3
Adjunctive Medication for Pump Safety
- The ADA recommends that all patients on insulin‑pump therapy receive a prescription for glucagon to treat severe hypoglycemia in case of pump failure. 4
Clinical Rationale for Using Lispro in Pumps
- Rapid‑acting insulin analogs such as lispro are the standard of care for insulin pumps because they provide superior post‑prandial glucose control compared with regular human insulin when delivered by CSII. Controlled trials cited by the ADA demonstrate this benefit. 1
- The ADA confirms that lispro’s stability in pump delivery systems has been validated, supporting its preferential use over regular insulin in pump therapy. 2
Prohibited Practices in Pump Reservoirs
- The ADA advises against mixing insulins in pump reservoirs; only pure rapid‑acting insulin analog formulations should be used. 1
Patient Selection and Training Requirements
- The ADA states that patients considered for pump therapy must be highly motivated, have completed comprehensive pump training, demonstrate competent self‑monitoring of blood glucose, and understand pump operation. 2
- The ADA emphasizes that patients must have access to a skilled multidisciplinary team experienced in CSII management. 1
Pregnancy Considerations
- The ADA notes that rapid‑acting insulin analogs are not FDA‑approved for use during pregnancy; this restriction pertains to the analog formulation itself rather than its specific use in an insulin pump. 2
Prescription Refills and Coverage
- The ADA recommends that prescriptions for insulin lispro include a refill schedule that aligns with the intended coverage period (e.g., 30‑90 days). 4
Insulin Pump Therapy Guidelines
Insulin Selection
- Rapid-acting insulin analogs, such as insulin aspart, lispro, or glulisine, are recommended for use in insulin pumps due to their quick onset of action, predictable absorption, and shorter duration, making them ideal for continuous subcutaneous insulin infusion (CSII) 5
- The American Diabetes Association, as reported in Diabetes Care, suggests that insulin pumps deliver continuous subcutaneous insulin infusion (CSII) and require insulin that can be safely delivered in small, frequent doses throughout the day 5
Pump Management and Safety
- The American Academy of Family Physicians recommends always carrying backup rapid-acting insulin syringes or pens in case of pump failure, which can lead to rapid ketoacidosis within hours since no long-acting insulin is on board 6
- The American College of Clinical Endocrinologists, as reported in Praxis Medical Insights, suggests that the pump delivers approximately 50% of total daily insulin as continuous basal infusion and 50% as meal boluses, with most pump reservoirs holding 200-300 units, providing 4-6 days of insulin for patients using 50 units daily 7
- Long-acting insulins, such as glargine, detemir, and degludec, are not used in pumps, as they are designed for once or twice daily injection, not continuous infusion, according to the American Diabetes Association, as reported in Diabetes Care 5